A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...

Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed approval for drugs to fill unmet needs, federal watchdogs said in a report.

To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...

FDA sets August ... subcutaneous dosing allows Alzheimer's patients to administer weekly treatment at home in 15 seconds. Get ...

The FDA accepted Biogen and Eisai’s BLA for a subcutaneous administration of the anti-amyloid antibody Monday as the partners ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...